Multicenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS)
Status: Recruiting
Location: See all (20) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:
• Female or male, age 18 or over
• Diagnosis of LAM based on ATS/JRS criteria
• Signed and dated informed consent
• On chronic therapy, newly treated or may be considered for therapy with mTOR inhibitors or previously intolerant of or having failed mTOR inhibitor therapy
Locations
United States
California
Stanford University Medical Center
RECRUITING
Stanford
Colorado
National Jewish Health
RECRUITING
Denver
Florida
Mayo Clinic Jacksonville
RECRUITING
Jacksonville
Georgia
Emory University School of Medicine
RECRUITING
Atlanta
Illinois
Loyola University Medical Center, Chicago
ACTIVE_NOT_RECRUITING
Maywood
Massachusetts
Brigham and Women's Hospital
RECRUITING
Boston
Michigan
University of Michigan
RECRUITING
Ann Arbor
Minnesota
Mayo Clinic Rochester
ACTIVE_NOT_RECRUITING
Rochester
Missouri
Washington University School of Medicine
RECRUITING
St Louis
New York
University of Rochester Medical Center
RECRUITING
Rochester
Ohio
University of Cincinnati
ACTIVE_NOT_RECRUITING
Cincinnati
Cleveland Clinic
ACTIVE_NOT_RECRUITING
Cleveland
Oregon
Oregon Health and Science University
ACTIVE_NOT_RECRUITING
Portland
Pennsylvania
University of Pennsylvania Medical Center
ACTIVE_NOT_RECRUITING
Philadelphia
South Carolina
Medical University of South Carolina
ACTIVE_NOT_RECRUITING
Charleston
Tennessee
Vanderbilt University Medical Center
ACTIVE_NOT_RECRUITING
Nashville
Texas
University of Texas Southwestern Medical Center
ACTIVE_NOT_RECRUITING
Dallas
University of Texas Health Center
ACTIVE_NOT_RECRUITING
Houston
Utah
University of Utah School of Medicine
ACTIVE_NOT_RECRUITING
Salt Lake City
Washington
Swedish Medical Center
ACTIVE_NOT_RECRUITING
Seattle
Contact Information
Primary
Susan McMahan Sellers, BSN, RN
susan.mcmahan@uc.edu
(513) 558-4376
Backup
Francis X McCormack, MD
frank.mccormack@uc.edu
(513) 558-0588
Time Frame
Start Date: 2015-03
Estimated Completion Date: 2025-07-31
Participants
Target number of participants: 600
Treatments
Everolimus
women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking everolimus as part of their clinical care
Sirolimus
women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking sirolimus as part of their clinical care
Related Therapeutic Areas
Sponsors
Collaborators: The LAM Foundation, Rare Diseases Clinical Research Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Leads: University of Cincinnati